Company research
Vor Biopharma Inc.
CIK 1817229Updated Nov 14, 2026
SecurityVOR · NASDAQ · equity
VOR price & chart
Loading TradingView…
NASDAQ:VOR on TradingView ↗About the company
Vor Bio is a clinical-stage biotechnology company transforming the treatment of autoimmune diseases. The Company is focused on rapidly advancing telitacicept, a novel dual-target fusion protein, through Phase 3 clinical development and potential commercialization to address serious autoantibody-driven conditions worldwide. For more information visit www.vorbio.com. Vor Bio routinely posts information that may be important to investors in the “Investors” section of its website. The Company encourages investors to consult that section of its website regularly.
In the news
Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) ↗
Recent filings
Financials
FY 2025 · USDSource
Source
Source
Source
Source
balance sheet · annual statements
| Line item | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q2 2024 | Q1 2026 | Q1 2025 | Q1 2024 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||
| AssetsUSD | 176,237,000Source | 115,991,000Source | 481,053,000Source | 205,371,000Source | 141,588,000Source | 506,746,000Source | 109,312,000Source | 167,030,000Source | 464,126,000Source | 142,891,000Source | 198,126,000Source | 299,366,000Source |
| Property, Plant and Equipment, NetUSD | 271,000Source | 7,474,000Source | 648,000Source | 0Source | 8,291,000Source | 565,000Source | 5,986,000Source | 9,165,000Source | 533,000Source | 6,581,000Source | 10,050,000Source | 12,634,000Source |
| Current assets: | ||||||||||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 160,462,000Source | 52,798,000Source | 107,855,000Source | 190,574,000Source | 76,076,000Source | 169,873,000Source | 50,047,000Source | 44,964,000Source | 396,486,000Source | 81,949,000Source | 31,360,000Source | 57,706,000Source |
| Assets, CurrentUSD | 172,486,000Source | 67,296,000Source | 475,107,000Source | 204,927,000Source | 90,256,000Source | 500,778,000Source | 64,847,000Source | 111,817,000Source | 458,105,000Source | 96,507,000Source | 140,803,000Source | 236,950,000Source |
| Operating Lease, Right-of-Use AssetUSD | 3,043,000Source | 36,296,000Source | 2,718,000Source | 24,000Source | 37,565,000Source | 2,827,000Source | 33,697,000Source | 38,816,000Source | 2,936,000Source | 35,007,000Source | 40,048,000Source | 44,444,000Source |
| Other Assets, NoncurrentUSD | 269,000Source | 2,512,000Source | 2,412,000Source | 420,000Source | 3,063,000Source | 2,408,000Source | 2,369,000Source | 4,819,000Source | 2,384,000Source | 2,383,000Source | 4,812,000Source | 2,925,000Source |
| LIABILITIES AND EQUITY | ||||||||||||
| LiabilitiesUSD | 2,401,724,000Source | 43,036,000Source | 681,250,000Source | 1,711,071,000Source | 43,508,000Source | 657,170,000Source | 43,243,000Source | 43,995,000Source | 628,438,000Source | 46,227,000Source | 47,402,000Source | 48,759,000Source |
| Stockholders’ equity: | ||||||||||||
| Common Stock, Value, IssuedUSD | 15,000Source | 7,000Source | 19,000Source | 13,000Source | 7,000Source | 19,000Source | 13,000Source | 7,000Source | 18,000Source | 13,000Source | 7,000Source | 7,000Source |
| Retained Earnings (Accumulated Deficit)USD | -2,875,833,000Source | -426,282,000Source | -1,435,367,000Source | -2,063,149,000Source | -398,723,000Source | -1,372,560,000Source | -489,480,000Source | -370,884,000Source | -1,152,975,000Source | -456,994,000Source | -340,080,000Source | -222,217,000Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | 12,000Source | 68,000Source | -922,000Source | 14,000Source | -70,000Source | -706,000Source | 23,000Source | -87,000Source | 41,000Source | 22,000Source | -77,000Source | -770,000Source |
| Stockholders' Equity Attributable to ParentUSD | -2,225,487,000Source | 72,955,000Source | -200,197,000Source | -1,505,700,000Source | 98,080,000Source | -150,424,000Source | 66,069,000Source | 123,035,000Source | -164,312,000Source | 96,664,000Source | 150,724,000Source | 250,607,000Source |
| Additional Paid in Capital, Common StockUSD | 650,319,000Source | 499,162,000Source | 1,236,073,000Source | 557,422,000Source | 496,866,000Source | 1,222,823,000Source | 555,513,000Source | 493,999,000Source | 988,604,000Source | 553,623,000Source | 490,874,000Source | 473,587,000Source |
| Liabilities and EquityUSD | 176,237,000Source | 115,991,000Source | 481,053,000Source | 205,371,000Source | 141,588,000Source | 506,746,000Source | 109,312,000Source | 167,030,000Source | 464,126,000Source | 142,891,000Source | 198,126,000Source | 299,366,000Source |
| Current liabilities: | ||||||||||||
| Liabilities, CurrentUSD | 18,839,000Source | 14,345,000Source | 24,814,000Source | 58,773,000Source | 13,801,000Source | 16,077,000Source | 16,727,000Source | 13,213,000Source | 25,171,000Source | 18,612,000Source | 15,572,000Source | 13,119,000Source |
| Operating Lease, Liability, CurrentUSD | 252,000Source | 4,163,000Source | 335,000Source | 0Source | 4,113,000Source | 307,000Source | 4,266,000Source | 3,957,000Source | 280,000Source | 4,215,000Source | 3,830,000Source | 3,272,000Source |
| Accounts Payable, CurrentUSD | 885,000Source | 1,316,000Source | 3,998,000Source | 669,000Source | 2,007,000Source | 1,043,000Source | 3,732,000Source | 2,325,000Source | 5,127,000Source | 1,505,000Source | 815,000Source | 1,772,000Source |
| Operating Lease, Liability, NoncurrentUSD | 2,807,000Source | 28,691,000Source | 2,542,000Source | 0Source | 29,707,000Source | 2,632,000Source | 26,516,000Source | 30,782,000Source | 2,720,000Source | 27,615,000Source | 31,830,000Source | 35,640,000Source |
| Additional Financial Items | ||||||||||||
| Accrued Liabilities, CurrentUSD | 17,702,000Source | 8,853,000Source | 20,481,000Source | 58,104,000Source | 7,656,000Source | 14,727,000Source | 8,685,000Source | 6,797,000Source | 19,764,000Source | 12,892,000Source | 10,877,000Source | 7,889,000Source |
| Cash, Cash Equivalents, and Short-term InvestmentsUSD | 170,500,000Source | 62,800,000Source | 466,100,000Source | 200,600,000Source | 85,900,000Source | 491,500,000Source | 60,000,000Source | — | 455,200,000Source | 91,900,000Source | — | — |
| Deferred Tax Liabilities, NetUSD | — | — | — | — | — | — | — | — | 880,000Source | 10,127,000Source | 11,702,000Source | 11,772,000Source |
cash flow · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | ||||||||||||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | — | — | — | — | — | — | -219,585,000Source | -32,486,000Source | -695,981,000Source | -116,914,000Source | -117,863,000Source | -92,094,000Source |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||||||
| Share-based Payment Arrangement, Noncash ExpenseUSD | — | — | — | — | — | — | 8,870,000Source | 1,933,000Source | 18,912,000Source | 9,847,000Source | 13,362,000Source | 10,695,000Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | — | — | — | — | — | — | -38,246,000Source | -31,066,000Source | -142,713,000Source | -99,660,000Source | -100,292,000Source | -85,144,000Source |
| Cash flows from investing activities: | ||||||||||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | — | — | — | — | — | — | -263,237,000Source | -230,000Source | -48,802,000Source | 96,857,000Source | 71,008,000Source | -94,091,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | — | — | — | — | — | — | 48,000Source | 231,000Source | 941,000Source | 229,000Source | 1,069,000Source | 8,462,000Source |
| Cash flows from financing activities: | ||||||||||||
| Payment, Tax Withholding, Share-based Payment ArrangementUSD | — | — | — | — | — | — | 2,000Source | 55,000Source | 254,000Source | 333,000Source | 1,187,000Source | — |
| Net Cash Provided by (Used in) Financing ActivitiesUSD | — | — | — | — | — | — | 74,870,000Source | -606,000Source | 503,807,000Source | 53,392,000Source | 2,938,000Source | 117,140,000Source |
| Payments of Ordinary Dividends, Common StockUSD | — | — | — | — | — | — | — | — | 0Source | 0Source | 0Source | 0Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | — | — | — | — | — | — | -226,613,000Source | -31,902,000Source | 312,292,000Source | 50,589,000Source | -26,346,000Source | -62,095,000Source |
| Additional Financial Items | ||||||||||||
| Share-based Payment Arrangement, ExpenseUSD | — | — | 8,029,000Source | 2,264,000Source | 9,399,000Source | 1,844,000Source | 8,870,000Source | 1,933,000Source | 18,912,000Source | 9,847,000Source | 13,362,000Source | 10,695,000Source |
| Cash, Cash Equivalents, and Short-term InvestmentsUSD | — | — | 170,500,000Source | 62,800,000Source | 466,100,000Source | 200,600,000Source | 491,500,000Source | 60,000,000Source | 455,200,000Source | 91,900,000Source | — | — |
| DepreciationUSD | — | — | — | 900,000Source | — | 2,100,000Source | 28,000Source | 825,000Source | 2,887,000Source | 3,528,000Source | 3,492,000Source | 2,525,000Source |
| Gain (Loss) on Disposition of Property Plant EquipmentUSD | — | — | — | — | — | — | 0Source | -1,000Source | -3,303,000Source | 18,000Source | — | — |
| General and Administrative ExpenseUSD | — | — | 13,965,000Source | 6,696,000Source | 21,933,000Source | 12,785,000Source | 17,565,000Source | 6,590,000Source | 50,110,000Source | 27,875,000Source | 31,721,000Source | 28,868,000Source |
| Investment Income, InterestUSD | — | — | 1,731,000Source | 954,000Source | 4,343,000Source | 537,000Source | 3,935,000Source | 805,000Source | 5,868,000Source | 4,271,000Source | 8,173,000Source | 1,324,000Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | -812,684,000Source | -27,559,000Source | -62,810,000Source | -1,573,669,000Source | -219,585,000Source | -32,486,000Source | -695,981,000Source | -116,914,000Source | -117,863,000Source | -92,094,000Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | — | — | -812,684,000Source | -27,559,000Source | — | -1,573,669,000Source | — | -32,486,000Source | — | — | -117,863,000Source | -92,094,000Source |
| Nonoperating Income (Expense)USD | — | — | -784,577,000Source | 954,000Source | -14,957,000Source | -1,299,385,000Source | -184,425,000Source | 805,000Source | -324,339,000Source | 4,271,000Source | 8,173,000Source | 1,324,000Source |
| Operating ExpensesUSD | — | — | 28,107,000Source | 28,513,000Source | 47,853,000Source | 274,284,000Source | 35,160,000Source | 33,291,000Source | 371,642,000Source | 121,185,000Source | 126,036,000Source | 93,418,000Source |
| Operating Lease, ExpenseUSD | — | — | — | — | — | — | 109,000Source | 1,310,000Source | 5,647,000Source | 5,041,000Source | 4,727,000Source | 6,435,000Source |
| Proceeds from Issuance of Common StockUSD | — | — | — | — | — | — | — | 0Source | 70,106,000Source | 275,000Source | 4,578,000Source | 4,451,000Source |
income statement · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Income (Loss)USD | — | — | -28,107,000Source | -28,513,000Source | -47,853,000Source | -274,284,000Source | -35,160,000Source | -33,291,000Source | -371,642,000Source | -121,185,000Source | -126,036,000Source | -93,418,000Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | -812,684,000Source | -27,559,000Source | -62,810,000Source | -1,573,669,000Source | -219,585,000Source | -32,486,000Source | -695,981,000Source | -116,914,000Source | -117,863,000Source | -92,094,000Source |
| Earnings Per Share, BasicUSD per share | — | — | -121.63Source | -8.05Source | -1.16Source | -251.24Source | -5.11Source | -5.21Source | -70.5Source | -1.7Source | -1.75Source | -2.33Source |
| Earnings Per Share, DilutedUSD per share | — | — | -121.63Source | -8.05Source | -1.16Source | -251.24Source | -5.11Source | -5.21Source | -70.5Source | -1.7Source | -1.75Source | -2.33Source |
| Weighted Average Number of Shares Outstanding, Basicshares | — | — | 6,681,794Source | 3,423,499Source | 54,304,456Source | 6,263,572Source | 43,011,544Source | 6,241,207Source | 9,871,866Source | 68,705,639Source | 67,191,973Source | 39,551,420Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | — | — | 6,681,794Source | 3,423,499Source | 54,304,456Source | 6,263,572Source | 43,011,544Source | 6,241,207Source | 9,871,866Source | 68,705,639Source | 67,191,973Source | 39,551,420Source |
| Additional Financial Items | ||||||||||||
| General and Administrative ExpenseUSD | — | — | 13,965,000Source | 6,696,000Source | 21,933,000Source | 12,785,000Source | 17,565,000Source | 6,590,000Source | 50,110,000Source | 27,875,000Source | 31,721,000Source | 28,868,000Source |
| Investment Income, InterestUSD | — | — | 1,731,000Source | 954,000Source | 4,343,000Source | 537,000Source | 3,935,000Source | 805,000Source | 5,868,000Source | 4,271,000Source | 8,173,000Source | 1,324,000Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | — | — | -812,684,000Source | -27,559,000Source | — | -1,573,669,000Source | — | -32,486,000Source | — | — | -117,863,000Source | -92,094,000Source |
| Nonoperating Income (Expense)USD | — | — | -784,577,000Source | 954,000Source | -14,957,000Source | -1,299,385,000Source | -184,425,000Source | 805,000Source | -324,339,000Source | 4,271,000Source | 8,173,000Source | 1,324,000Source |
| Operating ExpensesUSD | — | — | 28,107,000Source | 28,513,000Source | 47,853,000Source | 274,284,000Source | 35,160,000Source | 33,291,000Source | 371,642,000Source | 121,185,000Source | 126,036,000Source | 93,418,000Source |
| Operating Lease, ExpenseUSD | — | — | — | — | — | — | 109,000Source | 1,310,000Source | 5,647,000Source | 5,041,000Source | 4,727,000Source | 6,435,000Source |
| Research and Development ExpenseUSD | — | — | 14,142,000Source | 21,817,000Source | 25,920,000Source | 261,499,000Source | 17,595,000Source | 26,701,000Source | 321,532,000Source | 93,310,000Source | 94,315,000Source | 64,550,000Source |
Offerings
Registration 333-298767
Registration 333-295346
Registration 333-293052
Filing attachments
vor-ex99_1.htm · 8-K · 2026-11-12
Exhibit 99.1 Vor Bio Expands Strategic Partnership with RemeGen, Adding Next Generation, Long-Acting RC298 to BAFF/APRIL Franchise RemeGen’s expertise and next generation engineering expand Vor Bio’s leadership in the BAFF/APRIL field RC298 is a next generation, long-acting dual BAFF/APRIL inhibitor designed to combine high potency and extended half-life for potentially best-in-class efficacy and dosing RC298 is in IND-enabling development, with an initial regulatory filing anticipated in th…
Read attachment ↗d105320dex42.htm · S-3ASR · 2026-09-04
Exhibit 4.2 VOR BIOPHARMA INC., ISSUER AND [TRUSTEE], TRUSTEE INDENTURE DATED AS OF [•], 20 DEBT SECURITIES TABLE OF CONTENTS Page ARTICLE 1 DEFINITIONS 1 Section 1.01 Definitions of Terms 1 ARTICLE 2 ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE…
Read attachment ↗vor-ex99_1.htm · 8-K · 2026-06-08
EX-99.1 2 vor-ex99_1.htm EX-99.1 EX-99.1 Telitacicept Receives NMPA Conditional Approval for the Treatment of IgA Nephropathy in China First and only approved BAFF/APRIL-targeting therapy for IgA nephropathy (IgAN) Approval based on positive interim Phase 3 TELIGAN results generated by collaborator RemeGen and recently published in The New England Journal of Medicine IgAN marks the fourth indication approval for telitacicept BOSTON, Mass., June 8, 2026 (GLOBE NEWSWIRE) - Vor Bio (Nasdaq…
Read attachment ↗vor-ex99_2.htm · 8-K · 2026-06-08
EX-99.2 3 vor-ex99_2.htm EX-99.2 EX-99.2 Telitacicept Receives NMPA Approval for the Treatment of Sjögren’s Disease in China First regulatory approval for Sjögren’s disease (SjD) First and only approved therapy for SjD in China Approval based on positive Phase 3 results generated by collaborator RemeGen demonstrating statistically significant and clinically meaningful improvements in both ESSDAI and ESSPRI SjD marks the fifth indication approval for telitacicept BOSTON, Mass., June 8, …
Read attachment ↗vor-ex4_3.htm · 10-K · 2026-03-30
Exhibit 4.3 DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 The descriptions below of Vor Biopharma Inc.’s (“our” or “we”) common stock and provisions of our amended and restated certificate of incorporation (“Restated Certificate”) and amended and restated bylaws (“Bylaws”) are summaries and are qualified b…
Read attachment ↗vor-ex99_1.htm · 8-K · 2026-03-27
EX-99.1 4 vor-ex99_1.htm EX-99.1 EX-99.1 Vor Bio Announces $75 Million Private Placement with TCGX BOSTON, Mass., March 27, 2026 (GLOBE NEWSWIRE) - Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, announced today that it has entered into a securities purchase agreement to sell 5,338,078 shares of its common stock at a price of $14.05 per share in a private placement. Vor Bio anticipates the gross proceeds from the private plac…
Read attachment ↗